达格列净对心脏功能及运动时代谢与激素反应的影响
该双盲、安慰剂对照交叉研究纳入9例2型糖尿病患者,随机接受4周达格列净或安慰剂,洗脱期4周,随后进行两阶段恒定负荷运动试验并行动激素代谢分析及盲法经胸超声心动图。达格列净治疗期间运动时葡萄糖和乳酸较低、β-羟丁酸和生长激素较高,e'峰值升高,左房容积指数和右室e"降低,动脉僵硬度无差异。
要点
- 达格列净治疗4周后运动时葡萄糖和乳酸较安慰剂降低,β-羟丁酸和生长激素升高。
- 达格列净治疗期间肾上腺素、去甲肾上腺素和胰高血糖素与安慰剂无差异。
- 达格列净治疗4周后心脏功能改变出现迅速且可逆。
核心结论
- 运动时生长激素可能比儿茶酚胺更重要地驱动SGLT2抑制剂引起的从葡萄糖向脂肪酸代谢的转变。
- 4周交叉设计显示心脏功能改变出现迅速且可逆。
研究设计与样本
- 双盲、安慰剂对照交叉研究,洗脱期4周,9例2型糖尿病患者随机接受4周达格列净或4周安慰剂。
- 每种治疗后进行运动方案:连续两个10分钟阶段,恒定负荷分别对应40%和70%最大氧耗量(VO2max),同步进行激素和代谢分析;3天后行盲法经胸超声心动图。
主要发现
- 运动方案期间,达格列净治疗较安慰剂葡萄糖更低(P < .0001)、乳酸更低(P < .05)。
- 运动方案期间,达格列净治疗较安慰剂β-羟丁酸(BOBH)更高(P < .0005)、生长激素更高(P = .01)。
- 达格列净治疗较安慰剂胰岛素有降低趋势。
- 肾上腺素、去甲肾上腺素和胰高血糖素在两种治疗间无差异。
- 达格列净治疗较安慰剂平均二尖瓣环舒张早期峰值速度(e')增加(P = .03);左房容积指数和右室e"降低(分别为P = .045和P = .042);动脉僵硬度无差异(达格列净9.35 ± 0.60 m/s;安慰剂9.07 ± 0.72 m/s)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This work aimed to investigate the effect of the SGLT2 inhibitor, dapagliflozin (DAPA), on cardiac function and the metabolic and hormonal response to moderate exercise in people with type 2 diabetes. METHODS: This was a double-blind, placebo-controlled crossover study with a 4-week washout period. Nine participants were randomly assigned to receive either 4 weeks of DAPA or 4 weeks of placebo. After each treatment, they underwent an exercise protocol with 2 consecutive 10-minute stages at a constant load corresponding to 40% and 70% maximal oxygen consumption (VO2max), coupled with hormonal and metabolic analysis. A blinded transthoracic echocardiogram was performed 3 days later. RESULTS: During the exercise protocol, glucose and lactate were lower (P < .0001 and P < .05, respectively) and β-hydroxybutyrate (BOBH) and growth hormone (GH) were higher (P < .0005 and P = .01) following DAPA treatment compared to placebo. There was a trend for lower insulin with DAPA. Adrenalin, noradrenalin, and glucagon were not different. Following DAPA participants demonstrated an increased mean peak diastolic mitral annular velocity (e') in comparison to placebo (P = .03). The indexed left atrial volume and right ventricular e" were reduced following DAPA compared with placebo (P = .045 and P = .042, respectively). Arterial stiffness was not different between treatments (DAPA 9.35 ± 0.60 m/s; placebo 9.07 ± 0.72 m/s). CONCLUSION: During exercise, GH may be more important than catecholamines in driving the shift from glucose to fatty acid metabolism by SGLT2 inhibitors. The 4-week crossover design showed changes in cardiac function were rapid in onset and reversible.
引用
- Herring RA, Parsons I, Shojaee-Moradie F, et al. Effect of Dapagliflozin on Cardiac Function and Metabolic and Hormonal Responses to Exercise. J Clin Endocrinol Metab. 2023. PMID: 36274035. doi:10.1210/clinem/dgac617
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。